A clinical evaluation of plaque detection by a newly developed QLF (Quantified Light-Induced Fluorescence) based technology

Procter & Gamble (United States)0 个研究点目标入组 50 人开始时间: 2022年7月5日最近更新: 2022年8月5日

适应症

试验速览

暂无简介。

•1. Give written informed consent (if underage including her/his guardians) and given a signed copy of the Informed Consent form;
•2. Be at least 13 years of age;
•3. Have no fixed orthodontic appliance or attachments on both arches, Retainer in both arches are allowed;
•4. Provide written informed consent prior to participation and be given a signed copy of the informed consent form;
•5. Have plaque and at least one more of the following: demineralization/white spot lesions, remineralized caries at the fissures and accessory cusps, caries, tartar, fluorosis;
•6. Possess a minimum of 24 natural and crowned/bridges evaluable teeth including 8 frontal teeth;
•7. Be in good general health as determined by the Investigator/designee based on a review of the medical history/update for participation in the study;
•8. Agree not to participate in any other clinical study for the duration of this study;
•9. Agree to delay any elective dentistry, including dental prophylaxis, until study completion;
•10. Agree to return for the scheduled clinical visit and follow study procedures.

•1. Severe periodontal disease, as characterized by purulent exudate, generalized mobility, and/or severe recession;
•2. Active treatment for periodontitis;
•3. Use of antibiotics two weeks prior to study initiation;
•4. Any diseases or conditions that could be expected to interfere with the subject safely completing the study.
•5. Presence of cardiac pacemaker;
•6. Dental prophylaxis within 2 weeks prior to the screening visit.
•7. Fixed orthodontic appliance e.g. Multibrackets apparatus or attachments on at least one arch

发起方

Procter & Gamble (United States)